DL 473 is a 3-[(4-cyclopentyl-1-piperazinyl)iminomethyl] rifamycin SV derivative which inhibited staphylococci, streptococci (including Streptococcus faecalis, Listeria species, and Bacteroides species. DL 473 was less active than rifampin against these species. DL 473 did not inhibit Enterobacteriaceae nor most Pseudomonas species. A combination of DL 473 and vancomycin or nafcillin tested against staphylococci was primarily additive and antagonism was not encountered.
There has been an increased interest in the activity of rifamycin compounds against bacteria other than mycobacteria. Rifampin enters white cells and has been used to treat endocarditis in combination with anti-cell wall antibiotics (5).
Arioli and colleagues (1) Table 2 . DL 473 was four-to eightfold less active than rifampin against Staphylococcus aureus. For example, the DL 473 MIC against S. aureus was 0.1 ,ug/ml compared to a rifampin MIC of 0.025 jig/ml, or a DL 473 MIC of 0.8 ,ig/ml compared to 0.025 jig/ml. However, DL 473 did inhibit methicillin-resistant isolates, all at <0.2 ,ug/ml, and it also inhibited erythromycin-resistant S. aureus. The activity of DL 473 against Staphylococcus epidermidis was virtually identical to its activity against S. aureus. The comparable rifamycin MICs would be 0.001 and 0.025 ,ug/ml compared to 0.1 and 0.8 jig/ml for DL 473. DL 473 inhibited methicillin-and erythromycin-resistant S. epidermidis. DL 473 was comparable to ampicillin and vancomycin against S. faecalis and more active than those two compounds against Listeria species, but less active than rifampin. Rifampin was also two-to eightfold more active than DL 473 when tested against single isolates of Streptococcus faecium, Streptococcus mitis, and Streptococcus bovis.
The inoculum size had an effect upon the activity of DL 473. Table 3 demonstrates that there was great variability in the effect of increasing inoculum size to 107 from 105 CFUs.
Several isolates showed a greater than eightfold rise in MIC, but the most common increase was a fourfold increase in MIC values. The difference between MIC and MBC values for five isolates each of S. aureus, S. epidermidis, and S. faecalis ranged from no increase to an eightfold increase; for example, organisms with MICs of 0.01 ,ug/ml had MBC values of 0.01, 0.025, and 0.1 ,ug/ml. The MIC of DL 473 in the presence of 50%1o0 normal human serum for the aforementioned organisms was 3.1 1ug/ml compared to 0.01 ,ug/ml in Mueller-Hinton broth. Table 4 shows the effect of combination of DL 473 with vancomycin or nafcillin when tested against staphylococci. Against S. aureus and S. epidermidis the combination of DL 473 and nafcillin was additive, and neither synergy nor antagonism was noted. In contrast, vancomycin and DL 473 acted in a synergistic manner for 32 and 42% of the S. aureus and S. epidermidis strains, respectively. Antagonism was not seen. An example of synergy against S. aureus was a DL 473 MIC of 0.2 g±g/ml and a vancomycin MIC of 1.6 ,ug/ml with an MIC of the combined agents 0.025 pug/ml. We did not find antagonism as has been reported for some combinations of rifampin and vancomycin or penicillins (8) , but I did not determine bactericidal synergy concentrations.
The results of this study extend the earlier observations of Arioli et al. (1) . The in vitro activity of DL 473, although less than that of rifampin, is excellent against staphylococci, streptococci (including S. faecalis), Listeria species and Bacteroides species. DL 473 has shown better 50% effective dose values in mice than rifampin, which may be due to either its higher serum levels or longer half-life. The longer halflife may be a combination of greater protein binding and altered biliary excretion (2) . Clearly, the in vitro characteristics of the compound support further clinical studies of the compound in humans to determine whether its pharmacokinetic advantages (3) may be of value in human infections.
